should glp-1 agonists be open access Patents and regulatory exclusivities on receptor Glucagon-Like Peptide-1 Receptor Agonists in

doi: 10.2337/dc12-2006

The initial search yielded 1,929 records (PubMed: 29

All these emerging benefits have made GLP-1 RAs an important pharmacological drug

Short-acting GLP-1RAs like exenatide and lixisenatide are associated with transient (112 h) increases, causing a maximum heart rate increase of 810 beats per minute (bpm) 24 h after injection, which returned to baseline after approximately 1012 h, with a mean 24 h heart rate increase of approximately 12 bpm for both GLP-1RAs in healthy adults ( Linnebjerg et al

Advantage : Survodutide MASH / Liver Disease# Pemvidutide : Phase 2b IMPACT trial showed 59.1% MASH resolution at 1.2 mg and 52.1% at 1.8 mg vs 19.1% placebo at 24 weeks

For Type 2 diabetes patients with adequate beta cell function, GLP-1 medications can sometimes replace or delay the need for insulin therapy